Remember to review the limitations and plan exclusions and ask how copay assistance funds from a manufacturer are applied and how they affect a patient’s out-of-pocket cost.Living with a chronic condition is costly. Remind patients that they may have to dig deep into the fine print to determine if a specific health plan has a copay accumulator program.
![humira copay assistance humira copay assistance](https://ccopharma.com/wp-content/uploads/2018/10/18-300x300.png)
Now is the time to act! As we are within the open enrollment period, it is a great time to investigate other plans if patients are affected by this challenge.
![humira copay assistance humira copay assistance](https://ccopharma.com/wp-content/uploads/2019/01/ajovy.jpg)
Identify which month the patient will exceed the copay card benefit based on monthly copay cost and the yearly copay card benefit max.Counsel patients on their benefits for the specialty drug and how their financial obligation can be impacted during their therapy journey.Provide education to patients when you identify they are enrolled in plans that includes an accumulator adjustment program.Anticipate and prepare for an increase of copay accumulator plans in 2021.Investigate patient’s plan thoroughly during the benefit investigation process to identify plans that include an accumulator adjustment program.A maximizer has an advantage over an accumulator because it reduces or eliminates the patient’s out-of-pocket obligations.įor example: When a patient is enrolled in a maximizer plan, the plan will take into consideration the pharmaceutical manufacturer’s monthly coupon value and slightly increase the copayment amount due each month, resulting in patient out-of-pocket cost, deductible contribution, and out-of-pocket max.īest Practices for Providers to Address Copay Accumulators
#Humira copay assistance full#
Under a copay maximizer, the full value of the manufacturer’s copayment program is applied evenly throughout the benefit year. As a result, the patients, who are the customers of the payers, suffer financially.Ĭopay maximizers, while similar, are a bit different. It’s evident after reviewing the example above that the only real benefactors of the copay accumulator model are the payers. In addition to the increase in the manufacturer’s subsidy, the patient’s total out-of-pocket cost based on this example increases from $0 annually to $4,000 in order to satisfy the deductible, coinsurance, and out-of-pocket of the plan. The difference in the copay accumulator model is the increase in the manufacturer’s contribution and the decrease in the payer’s expense. The drug in this example is $2,000 per month: For this example, the patient has a $2,000 deductible, 20% coinsurance, and a $4,000 out of pocket max. Does this mean the payer/ pharmacy benefit manager (PBM) is double-dipping?īelow is an example of a historical payment model for medication versus an accumulator model. These programs support beneficiaries with commercial insurance, but they cannot be used by enrollees in government programs such as Medicare Part D.Ī copay accumulator – or accumulator adjustment program – is a strategy used by insurance companies and Pharmacy Benefit Managers (PBMs) that stop manufacturer copay assistance coupons from counting towards two costs: 1) the deductible and 2) the maximum out-of-pocket spending.Īs drug manufacturers attempt to create programs to subsidize out-of-pocket cost for patients, the payers reduce the value of these programs by exhausting such funds while also requiring the patients to pay their deductibles and coinsurance up to their out-of-pockets to obtain their medications.
![humira copay assistance humira copay assistance](https://images.ctfassets.net/decnlygd8vub/4AdCQtFkEyOiGZ70nZdS69/2a9d23d9cef5dab64d8b3784a17e26d7/Enbrel_Color_Logo.png)
Pharmaceutical manufacturers offer copayment offset/assistance programs ( also called copay cards or coupons) that cover the beneficiary’s out-of-pocket costs for a brand-name drug. Additionally, patients who continue treatment may incur significant debt for long term costly treatments. This hardship can increase the likelihood of treatment non-adherence, and can ultimately lead to advanced disease state. Copay accumulators have been present in the specialty pharmacy space for oral drugs for some time, causing many challenges for chronically ill patients as they fall under financial hardship.
![humira copay assistance humira copay assistance](https://images.rxlist.com/images/rxlist/enbrel37.gif)
Written by Angie Baker and Stef Parks, Leaders in Patient Access and ReimbursementĪs many drug manufacturers continue to develop new and innovative therapies for multiple disease states, we continue to see an evolution in the system through which payers (insurance companies/PBMs) use to process and pay claims.